JANX Janux Therapeutics
- 62.430
- +4.240+7.29%
- 60.800
- -1.630-2.61%
Janux Therapeutics News
Janux Therapeutics Gains Amid Renewed Takeover Speculation
Janux Therapeutics Jumps as Much as 28% on Heels of Deciphera Buyout Deal
Janux a New Buy at Jones on Lead Assets for Solid Tumors
A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts
In the latest quarter, 6 analysts provided ratings for Janux Therapeutics (NASDAQ:JANX), showcasing a mix of bullish and bearish perspectives.Summarizing their recent assessments, the table below illu
Express News | JonesTrading Initiates Coverage On Janux Therapeutics With Buy Rating, Announces Price Target of $70
Janux Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 34.98% JonesTrading → $70 Initiates Coverage On → Buy 03/21/2024 19.55% BTIG → $62 Initiates Co
Express News | Janux Therapeutics Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $70
Buy Rating Affirmed for Janux Therapeutics on Innovative Oncology Treatments and M&A Potential
Express News | Janux Therapeutics Shares Are Trading Higher on Continued Strength Following Wednesday Reports Suggesting the Company Is Said to Weigh a Possible Sale
Janux Therapeutics (JANX) Is on the Move, Here's Why the Trend Could Be Sustainable
Why Janux Therapeutics Stock Is Crushing It This Week
Janux Therapeutics Rallies Another 10%+ on Reports of a Possible Takeover
Janux Therapeutics rallied more than 10% for the second straight session Thursday as investors continued to bid up the biotech amid a report that the company might be up for sale.
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ:FAST) fell sharply during Thursday's session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9
Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?
Janux Therapeutics Inc (NASDAQ:JANX) shares are trading higher following Wednesday's reports suggesting the company is considering a possible sale following interest from larger pharmaceutical firms.
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) rose sharply during Thursday's session. Enliven Therapeutics an
Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet
Shares of Janux Therapeutics, Inc. (JANX) have gained 11.8% over the past four weeks to close the last trading session at $44.62, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication.
Express News | Janux Therapeutics Shares Are Trading Higher Following Wednesday Reports Suggesting the Company Is Said to Weigh a Possible Sale
Analysts' Top Healthcare Picks: Humacyte (HUMA), Janux Therapeutics Inc (JANX)
Why Janux Therapeutics Stock Soared as the Market Sagged Today
Clinical-stage biotech Janux Therapeutics (JANX 12.06%) was a standout title on a gloomy Wednesday stock market.
Sector Update: Health Care Stocks Slipping Late Afternoon
Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index shedding 0.9% and the Health Care Select Sector SPDR Fund (XLV) falling 1.1%. The iShares Biotechnology ETF (IBB)
Analysis
Price Target
No Data
